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EVALUATION OF AFFINITY MICROCOLUMNS CONTAINING
HUMAN SERUM ALBUMIN FOR RAPID ANALYSIS OF DRUGPROTEIN BINDING
Michelle J. Yoo, John E. Schiel, and David S. Hage*
Department of Chemistry University of Nebraska-Lincoln Lincoln, NE 68588-0304 (U.S.A.)

Abstract
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This study examined the use of affinity microcolumns as tools for the rapid analysis and highthroughput screening of drug-protein binding. The protein used was immobilized human serum
albumin (HSA) and the model analytes were warfarin and L-tryptophan, two solutes often used as
site-specific probes for drug binding to Sudlow sites I and II of HSA, respectively. The use of HSA
microcolumns in binding studies was examined by using both zonal elution and frontal analysis
formats. The zonal elution studies were conducted by injecting the probe compounds onto HSA
microcolumns of varying lengths while measuring the resulting retention factors, plate heights and
peak asymmetries. A decrease in the retention factor was noted when moving from longer to shorter
column lengths while using a constant amount of injected solute. However, this change could be
corrected, in part, by determining the relative retention factor of a solute versus a reference compound
injected onto the same microcolumn. The plate height values were relatively consistent for all column
lengths and gave an expected increase at higher linear velocities. The peak asymmetries were similar
for all columns up to 1 mL/min but shifted to larger values at higher flow rates and when using short
microcolumns (e.g., 1 mm length). The association equilibrium constants and number of binding
sites estimated by frontal analysis for warfarin with HSA were consistent at the various columns
sizes that were tested and gave good agreement with previous literature values. These results
confirmed affinity microcolumns provide comparable results to those obtained with longer columns
and can be used in the rapid analysis of drug-protein binding and in the high-throughput screening
of such interactions.
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1. Introduction
Interactions between drugs and serum proteins are important in determining the transport,
distribution, metabolism, excretion and activity of many pharmaceutical agents in the body
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[1–4]. The importance of these interactions has resulted in the development of numerous
methods to examine such binding [1–7]. Human serum albumin (HSA) is the most abundant
plasma protein and is involved in the transport of many drugs and small solutes [1,4]. Two
solutes that are often used as site-selective probes in drug binding studies with HSA are warfarin
and L-tryptophan [8,9]. Warfarin is an anticoagulant drug with two enantiomers, (R)- and
(S)-warfarin, that both bind to Sudlow site I of HSA with an association equilibrium constant
(Ka) on the order of 105–106 M−1 [4,5,7,10,11] The interaction between warfarin and HSA has
been previously studied by several methods [6,12,13]. L-Tryptophan binds to Sudlow site II
of HSA with a Ka between 104 and 105 M−1 and has also been examined by many techniques
[4,14].
One method that has been used increasingly in recent years to study drug-protein interactions
is high-performance affinity chromatography (HPAC) [10,15–22]. HPAC is a
chromatographic technique that uses a biologically-related ligand (e.g., a protein such as HSA)
as a stationary phase [23]. HPAC columns containing immobilized HSA have been shown in
many studies to give comparable results to those obtained by methods that use soluble HSA,
such as equilibrium dialysis and ultrafiltration [6,8,9,17,23]. Both frontal analysis (or frontal
affinity chromatography, FAC) and zonal elution have been employed as means for conducting
such experiments on traditional HPAC columns (i.e., columns with typical lengths of 5–10 cm
and inner diameters of 2.1–4.6 mm) [15,16,23,24].
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A few recent studies have examined drug-protein interactions by using smaller affinity columns
[8,9,22,24,25]. One study utilized affinity columns with dimensions of 250 μm i.d. × 1 cm for
work with FAC and mass spectrometry in the study of biomolecular interactions [22]. Another
report employed affinity columns with dimensions of 250 μm i.d. × 3 cm for the highthroughput screening of mixtures of modified β-galactopyranosides by using FAC and
electrospray mass spectrometry [25]. Smaller monolithic affinity columns have been used in
related studies. One report used a 4.5 mm i.d. × 6 mm affinity monolith to capture Eschericha
coli bacteria [26]. Another recent report explored the use of zonal elution studies with affinity
silica monoliths having sizes of 4.6 mm i.d. and lengths of 3–5 mm for use with immobilized
HSA and the high-throughput analysis of drug-protein interactions [27]. All of these previous
reports suggest that small affinity columns can be employed in such work; however, no
systematic comparison between the binding data obtained with these small columns and the
data obtained with larger affinity columns has been made, particularly in the case of FAC. In
addition, the range of column sizes that can be successfully used in such experiments in work
with silica particles has not yet been determined for either FAC or zonal elution studies.
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In this study, affinity microcolumns of various lengths and containing silica particles will be
used to study drug-protein interactions. HSA will be used as the immobilized protein and
warfarin and L-tryptophan will be the model solutes. The use of these columns in both zonal
elution and frontal analysis will be considered and the results will be compared to those
obtained with longer affinity columns. In the zonal elution studies, the effect of column length
on the measured retention, efficiency and peak asymmetry for each injected analyte will be
investigated. For frontal analysis, the effect of column size on the measured binding capacities
and affinities will be considered. The results of this report should provide a better understanding
of the size parameters that are required to study drug-protein interactions using affinity
microcolumns, as well as the potential advantages and limitations of affinity microcolumns in
such research.
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2. Experimental
2.1 Reagents
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The HSA (Cohn fraction V, essentially fatty acid free, ≥ 96% pure), racemic warfarin (98%),
R-warfarin (≥ 97%), and L-tryptophan (> 98%) were from Sigma (St. Louis, MO, USA).
Nucleosil Si-300 silica (300 Å pore size, 7 μm particle size) was purchased from Macherey
Nagel (Düren, Germany). Reagents for the bicinchoninic acid (BCA) protein assay were from
Pierce (Rockford, IL, USA). All buffers and aqueous solutions were prepared using water from
a Nanopure system (Barnstead, Dubuque, IA, USA) and filtered using Osmonics 0.22 μm nylon
filters from Fisher (Pittsburgh, PA, USA).
2.2 Apparatus
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The chromatographic system consisted of an isocratic HPLC pump (Jasco, Easton, MD, USA),
a Dynamax solvent delivery system (Rainin, Woburn, MA, USA), a six-port Lab Pro valve
(Rheodyne, Cotati, CA, USA), and a UV-2075 detector (Jasco, Easton, MD, USA). An Alltech
water jacket (Deerfield, IL, USA) and a circulating water bath from Fisher (Pittsburgh, PA,
USA) were used to maintain a temperature of 37.0 (± 0.1) °C for the chromatographic system
during all experiments described in this report. The columns were packed using an Alltech
slurry packer. Column lengths of 3 mm or less used a frit-in-column design, as described in
Ref. [28]; longer columns were prepared using traditional stainless steel HPLC housings and
end fittings. Chromatographic data were collected and processed using in-house programs
written in LabView 5.1 (National Instruments, Austin, TX, USA).
2.3 Methods
The stationary phase used in these studies consisted of silica particles containing immobilized
HSA. To make this material, Nucleosil Si-300 silica was first converted into a diol form, as
described previously [29]. HSA was then immobilized onto this diol silica by using the Schiff
base method [10,30]. The final HSA silica was stored in pH 7.4, 0.067 M potassium phosphate
buffer at 4 °C until use. A control support was prepared in the same method but with no HSA
being added during the immobilization step.
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Small portions of the HSA silica and control support were washed with water and dried under
vacuum at room temperature. These dried samples were analyzed in triplicate using a BCA
protein assay [31], using HSA as the standard and the control support as the blank. The final
protein content of the HSA silica was found to be 51 (± 3) mg HSA per gram of silica. The
remaining portions of the original HSA silica and control support were downward slurry packed
at 4000 psi (28 MPa) for 40 min into their respective columns using pH 7.4, 0.067 M potassium
phosphate buffer as the packing solution. The inner diameter of all the columns was 2.1 mm,
but the column length was varied. The effective column lengths were 1, 2, 5, 10, and 20 mm
(note: in preliminary studies with the given analytes, no significant changes in the measured
binding parameters were noted when increasing the column length from 20 mm to 50–100 mm,
indicating that it was not necessary to examine columns with these longer sizes in this present
study).
Each column was placed in a water jacket and connected to a circulating water bath for
temperature control. The columns were stored at 4 °C in pH 7.4, 0.067 M phosphate buffer
when not in use. These columns were used within a period of 3 months and have been previously
noted to be stable for up to one year under the storage and experimental conditions that were
used in this study [32]. All mobile phases for the chromatographic studies were prepared from
pH 7.4, 0.067 M phosphate buffer and were degassed for 25 min prior to use. The solutions of
warfarin and L-tryptophan were also prepared in this buffer. Solutions of warfarin in pH 7.4,
0.067 M phosphate buffer are known to be stable for several days when stored at 4 °C and were
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used within this period of time [11]. Solutions of L-tryptophan in this buffer were prepared
fresh daily due to the limited stability of this analyte under these mobile phase conditions, as
noted in previous studies [9].
The zonal elution studies were typically performed by injecting 5 μL of either 20 μM R-warfarin
or 20 μM L-tryptophan at 0.1–5 mL/min onto the HSA and control columns. In preliminary
studies, sample concentrations ranging from approximately 5–60 μM warfarin or L-tryptophan
were also employed. The 20 μM sample concentration that was eventually selected for Rwarfarin and L-tryptophan was chosen because of its ability to give easily detectable peaks for
both these analytes and its creation of only small changes (i.e., less than 5–6% variation) in
the measured retention factors on the 20 mm long column when compared when to work at
lower sample concentrations. The wavelengths used for absorbance detection were 308 nm for
R-warfarin, 280 nm for L-tryptophan, and 205 nm for sodium nitrate (i.e., a void volume
marker). The void time of the system was determined by making 5 μL injections of 25 μM
sodium nitrate in pH 7.4, 0.067 M phosphate buffer. The central moment, second moment, and
asymmetry of each peaks was determined by using Peakfit 4.12 (Systat Software, San Jose,
CA, USA). The retention factor and plate height measurements were corrected for the extracolumn void time of the chromatographic system and extra-column band broadening by using
results obtained for 5 μL injections of 25 μM sodium nitrate in pH 7.4, 0.067 M phosphate
buffer with no column present.
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Frontal analysis studies were conducted by using two pumps. The first pump was used to apply
only buffer (i.e., pH 7.4, 0.067 M potassium phosphate buffer) to the desired column; the second
pump was used to apply a solution containing a known concentration of the analyte (e.g.,
racemic warfarin) in this buffer. After a breakthrough curve had been obtained, only pH 7.4,
0.067 M potassium phosphate buffer was applied to the column to wash and elute the retained
drug. Identical studies were carried out on a control column to correct for the void time of the
system and for any secondary interactions between warfarin and the support, which were
typically less than 5% of the total column binding capacity. In the frontal analysis studies, the
concentrations of racemic warfarin that were used ranged from 1–10 μM and these solutions
were applied at flow rates between 0.2 and 2 mL/min. The wavelength used for absorbance
detection through the frontal analysis experiments was 308 nm. The mean breakthrough point
of each frontal analysis curve was determined by the equal area method [23] using Labview.

3. Results and discussion
3.1. Zonal elution studies of analyte retention on HSA microcolumns
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Zonal elution methods are often used to examine the binding of drugs with proteins such as
HSA [21]. For instance, retention factors for injected analytes can be used under appropriate
flow rate and elution conditions to estimate the percent of binding of an injected solute to an
immobilized protein [24]. In addition, Eqn. (1) shows how the retention factor (k) is related to
the global affinity constant for an injected solute with an immobilized protein [33].

(1)

In this equation, KA1 through KAn are the association equilibrium constants for binding sites 1
through n, n1 through nn represent the number of each type of site in the column, mL is the
moles of binding sites in the column, and VM is the column void volume (note: in this case,
the global association equilibrium constant is the summation of the KAn terms). In addition,
zonal elution studies and measurements of solute retention factors are often employed in
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competition studies to determine the location of the binding sites for a solute on HSA through
the use of site-selective probes such as warfarin and L-tryptophan [21,23,24].
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The retention of R-warfarin and L-tryptophan on HSA microcolumns of various lengths was
studied by performing zonal elution studies. The observed retention times for R-warfarin were
10.3 min, 2.4 min, and 46 s for the 2 cm, 5 mm, and 1 mm long columns at 0.5 mL/min,
respectively. The observed retention times for L-tryptophan were 77, 33, and 22 s for the 2 cm,
5 mm, and 1 mm long columns at 0.5 mL/min, respectively. This information demonstrated
the relative range of elution times that would be expected on these microcolumns for analytes
such as L-tryptophan and warfarin with Ka values for HSA in the range of 104–105 M−1 or
105–106 M−1, respectively.
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Figures 1 and 2 show how varying the flow rate affected the retention factor measured for Rwarfarin and L-tryptophan on the microcolumns with lengths of 2 cm, 5 mm and 1 mm (note:
similar trends were noted for the other columns examined in this study). For R-warfarin, the
average retention factors obtained at all flow rates on the 2 cm, 5 mm, and 1 mm long columns
were 82 (± 4), 57 (± 6), and 38 (± 8), respectively (note: the numbers in parentheses represent
1 S.D.). For L-tryptophan on the 2 cm, 5 mm, and 1 mm long columns, the average retention
factors at all samples flow rates were 7.4 (± 0.7), 4.6 (± 1.4), and 1.6 (± 0.8). The decrease in
the measured retention factors noted for both these analytes as the column length decreased
was found through sample loading studies to be related to the increase in sample loading that
occurred as a fixed amount of solute was injected onto each of these columns, thus introducing
non-linear elution conditions.
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Changing the amount of injected sample in proportion to the column size would be one
approach for minimizing the change that was noted in retention when using smaller HSA
microcolumns. However, one difficulty with this approach is that the analytes will also be more
difficult to detect as their injected quantities are decreased in proportion to column size. The
use of a relative comparison of retention factors, such as is achieved by using the selectivity
factor (α), was considered as an alternative means for adjusting for changes in analyte retention
with column size. In this approach, the retention factor for the analyte of interest can be
compared to the retention factor for a reference substance that is injected onto the same column
under the same flow rate conditions. An example of this approach is given in Figure 3, in which
the relative retention of R-warfarin versus L-tryptophan was found by taking the ratio of their
apparent retention factors and calculating the selectivity factor, where α = (kR-Warfarin)/
(kL-Tryptophan). As shown in Figure 3, the selectivity factor for these two solutes showed no
apparent changes in going from a column length of 2 cm to 5 mm, but did show a slight increase
in going from a length of 5 mm to 2 mm and a larger increase in going to a length of 1 mm.
These results indicated that the use of a retention factor ratio for an analyte versus a reference
compound injected onto the same column could be used, at least in part, to help correct for
column overloading effects that occur as smaller affinity columns are used for binding studies.
This data also indicates that a retention factor ratio could be used with small affinity columns
to quickly determine the relative affinity of an unknown compound by comparing it to a
reference solute with a known affinity for the ligand within the column.
The results in Figures 1–3 all demonstrate that there will be a loss in precision for the
measurement of either absolute retention factors or relative retention factors as the size of an
HSA microcolumn is decreased. As an example, the precision of the average measured
retention factors for R-warfarin changed from ± 1% to ± 5% when comparing the 2 cm and 1
mm long columns. The precision for the measured retention factors for L-tryptophan decreased
from ± 3% to ± 12% when going from the 2 cm to 1 mm long columns. Similar trends have
been noted in work with carbamazepine and R-warfarin on silica monolith columns containing
immobilized HSA [27]. The precision in the retention factor ratio (i.e., selectivity factor) for
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R-warfarin versus L-tryptophan changed from 3% to 15% in going from the 2 cm to 1 mm long
columns. The loss of precision in these cases is related to the shorter times that are allowed for
data collection with the smaller columns; however, the decrease in analysis time is still an
advantage as long as the measured retention or selectivity still has sufficient precision for the
desired application. In the case of HSA, high precision work would require the use of 2 cm or
longer columns, while high-throughput screening of binding properties could still make use of
the data that are obtained with shorter HSA columns.
3.2. Band-broadening and peak asymmetry for analytes on HSA microcolumns
Band-broadening and peak asymmetry are two other parameters that can be used in zonal
elution studies with HPAC to obtain information on biological interactions. Such
measurements can be used to examine the rate at which a solute interacts with an immobilized
ligand or as part of scheme for determining both rate constants and equilibrium constants for
a biomolecular interaction [23,33]. This work has included the use of HSA columns in such
measurements [33]. As a result, the effect of using smaller lengths in HSA columns on bandbroadening and peak asymmetry measurements was also considered in this report. For instance,
Eqn. (2) shows how plate height measurements can be related to the dissociation rate constant
kd for an analyte from an immobilized ligand [33],
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(2)

where Hk is the plate height contribution due to stationary phase mass transfer, u is the linear
velocity of the mobile phase in the column, and k is the retention factor for the injected solute.
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Figure 4 shows some plate height plots that were obtained for injections of R-warfarin for the
2 cm, 5 mm, and 1 mm long columns. Similar results were noted for L-tryptophan and for the
other columns used in this work. For linear velocities that ranged from 0.027 to 0.16 cm/s, the
plate height varied from 0.027 to 0.23 cm, 0.020 to 0.20 cm, and 0.031 to 0.13 cm for the 2
cm, 5 mm, and 1 mm long HSA columns, respectively, when using R-warfarin as the injected
analyte. These values compared well with a previously-reported plate height of 0.02 cm that
was measured for 3 mm × 4.6 mm i.d. silica monolith columns containing immobilized HSA
[27]. As expected, the silica particle-based columns used in this current study shifted to higher
plate height values as linear velocity increased. For the same range of linear velocity values as
listed earlier, the plate height values measured when using L-tryptophan were 0.018 to 0.81
cm, 0.008 to 0.39 cm, and 0.005 to 0.031 cm. The corresponding number of theoretical plates
on the 2 cm, 5 mm, and 1 mm long columns ranged from 9 to 73, 3 to 25, and 1 to 3 for Rwarfarin and 25 to 113, 12 to 62, and 1 to 21 for L-tryptophan over the given range of linear
velocities.
Figure 5 shows the effect of flow rate on the measured peak asymmetry at 10% of the maximum
for R-warfarin on the 2 cm and 1 mm long columns. Similar results were noted for L-tryptophan
and for the other columns used in this work. It was found that the asymmetry was relatively
consistent across all tested flow rates for the 2 cm long column, with a variation of only 12%
from 0.25–5 mL/min. Similar peak asymmetry values were obtained even on the 1 mm long
column at moderate flow rates (i.e., 0.25–1.0 mL/min); however, this value did increase by
roughly two-fold as the flow rate was increased to 5 mL/min. The other HSA microcolumns
that were examined followed the same trend in asymmetry values; similar results were also
seen when using L-tryptophan as the injected analyte. These results demonstrate that affinity
microcolumns can be used at even moderate flow rates without creating any appreciable
compromise in peak shape for HSA microcolumns.
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3.3 Frontal analysis studies of solute binding on HSA microcolumns
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Frontal analysis is a second tool that is commonly used with HSA columns for binding studies.
One advantage of frontal analysis is that it can use, and actually requires, analyte concentrations
that are sufficient to eventually saturate the column. Frontal analysis is also useful in that it
can directly provide information on both the equilibrium constants and binding capacities for
biomolecular interactions [15,23,33].
This section of this report used frontal analysis to examine the binding of racemic warfarin to
HSA columns of varying lengths and using flow rates that ranged from 0.2–2 mL/min. Figure
6 shows typical frontal analysis curves that were obtained using 2 cm, 5 mm, and 1 mm long
HSA columns. Figures 6(a) and 6(b) show the results that were obtained at a single flow rate
(i.e., 0.5 mL/min), at which the breakthrough times noted for warfarin varied from 4.2–9.5 min
and 30–45 s for the 2 cm and 1 mm long columns. Compared to the 2 cm column, the
breakthrough times obtained for the 1 mm column were 8 to 13-fold lower for each respective
applied concentration at the given flow rate. The difference in times can be attributed to the
difference in protein content across all column lengths. The 2 cm long column contained 24
(± 2) nmol HSA compared to 1.2 (± 0.1) nmol HSA for the 1 mm long column, which is roughly
20-fold less protein.
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There was also a noted difference in sample volume between column lengths. For example,
0.53 – 0.63 mL of warfarin was needed to form a breakthrough curve for the 5 mm long HSA
column. In comparison, the 2 cm long HSA column needed 2.8 – 2.9 mL of warfarin. This
four- to five-fold decrease in sample volume shows that a lower amount of volume was required
to saturate the column with decreasing column length, which led to a decrease in the amount
of sample needed to obtain the similar results in frontal analysis studies. The average
breakthrough volumes for 5 μM warfarin were 2.8 (± 0.1), 1.30 (± 0.03), 0.69 (± 0.06), 0.43
(± 0.04), and 0.29 (± 0.03) mL for the 2 cm, 1 cm, 5 mm, 2 mm, and 1 mm long HSA columns
at various flow rates.
Figure 6(c) illustrates the effect of changing only the flow rate during frontal analysis studies
on an HSA microcolumn. In this case, a 5 μM solution of warfarin was applied to the 1 mm
long HSA microcolumn at flow rates ranging from 0.2–2 mL/min. Similar results were obtained
on the other columns used in this report. As would be expected, an increase in flow rate caused
a decrease in the breakthrough time obtained for each curve, as demonstrated in Figure 6(c)
by the shift from right-to-left as the flow rate was increased. In this situation, an increase in
flow rate from 0.2 to 2 mL/min have a decrease in breakthrough time from 159 s to 19 s (i.e.,
an eight-fold decrease in overall breakthrough time under the conditions used in this particular
study).
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Figure 7 shows double-reciprocal plots that were obtained when the data for warfarin on the 2
cm and 1 mm long HSA microcolumns at 0.5 mL/min were analyzed according to Eqn. (3),
which is based on a 1:1 binding model [23].

(3)

In Eqn. (3), mLapp is the apparent moles of analyte required to saturate the column, [A] is the
concentration of applied analyte, and mL is the moles of binding sites in the column. Eqn. (3)
predicts that a plot of 1/mLapp versus 1/[A] with linear response will give a slope equal to 1/
(KamL) and an intercept of 1/mL for a system with one-site binding. This type of relationship
makes it possible to calculate the association equilibrium constant for this interaction and the
total moles of binding sites in the column. Both Eqn. (3) and its corresponding binding model
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have been used successfully in past work in examining binding of warfarin to HSA on longer
HPAC columns than those used in this current report [8,23,33]. Similar agreement between
Eqn. (3) and frontal analysis results that were obtained with HSA microcolumns was noted
under the conditions utilized in this current study.
Using the slopes and intercepts measured for plots like those in Figure 7, the binding capacity
(mL) and association equilibrium constant (Ka) were determined for R-warfarin on each HSA
microcolumn at various flow rates. The results are summarized in Table 1. As expected, the
binding capacity decreased in proportion to column size. For example, the measured binding
capacity for the 1 mm long HSA column was around twenty-fold less than it was for the 2 cm
long HSA column. However, the precision of binding capacity measurements decreased as
column length decreased. For the 2 cm long HSA column, the precision ranged from ± 4.3%
to ± 4.7% at the flow rates that were examined, with an average precision of ± 4.4%. The 1
mm long column gave a precision that ranged from ± 15% to ± 25% at the same flow rates,
with an average of ± 19%. This decrease in precision is again thought to be due to the decrease
in amount of time and stationary phase that is available for drug binding when using the affinity
microcolumns.
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It was noted in Table 1 that there was relatively good agreement in the average Ka values that
were obtained for each HSA microcolumn. All of these results also agreed with literature values
of 2.1 × 105 to 2.6 × 105 M−1 for R- and S-warfarin, or an average of approximately 2.4 ×
105 M−1 for racemic warfarin [6,8,11]. The Ka values obtained from all columns at flow rates
of 0.2–2 mL/min were between 2.0 and 3.4 × 105 M−1, with the precision ranging from ± 5%
to ± 42%. The average precision of Ka values obtained at individual flow rates for the 2 cm
long column was ± 5%, while the 1 mm column had ± 25% precision. From these results, it
was concluded that reliable estimates of mL and Ka by frontal analysis can be obtained at flow
rates as high as 2 mL/min and with columns as short as 1 mm.

4. Conclusions
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This work studied the effect of column length on zonal elution and frontal analysis studies to
examine drug-protein interactions. Zonal elution studies of R-warfarin and L-tryptophan
showed that the retention factor of each analyte shifted to smaller values as column length
decreased, but stayed fairly consistent across various flow rates. The ratio of the retention
factors, or selectivity factor, for R-warfarin versus L-tryptophan also appeared to be fairly
consistent for most HSA microcolumns versus a reference 2 cm long HSA column, although
a larger increase was seen for 1 mm long columns. Band-broadening studies showed that as
column length increased, the plate height values obtained at various flow rates were similar
for the various columns that were studied. In addition, the peak asymmetries obtained with
short and long microcolumns were consistent at low to moderate flow rates, but an increase in
peak asymmetry was noted at high flow rates. For each of these measured parameters, the
precision decreased as shorter column lengths were used.
This work also considered the effect of column length on frontal analysis studies of racemic
warfarin using HPAC. It was found that all column lengths (1 mm to 2 cm) could be used to
obtain reliable estimates of association equilibrium constants. The best estimate for the
association equilibrium constant of warfarin at Sudlow site I of HSA was 2.6 (± 0.6) × 105
M−1 at pH 7.4 and 37 °C, which compares well with previous results obtained with longer HSA
columns (e.g., see Ref. [6]). From these studies, there is now a clear indication that using
microaffinity columns in place of traditional longer columns does not compromise the accuracy
of frontal analysis measurements for faster analysis times. These results show that the faster
analysis times and slight decrease in precision obtained with HSA microcolumns make these
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attractive tools for use in rapid studies of drug-protein binding or high-throughput screening
of drug candidates with proteins such HSA.
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Figure 1.

Retention factors measured for R-warfarin at various flow rates for 5 μL injections of 20 μM
R-warfarin onto HSA microcolumns with lengths of (a) 2 cm, (b) 5 mm, or (c) 1 mm and an
inner diameter of 2.1 mm. Other experimental conditions are given in the text. The error bars
represent a range of ± 1 S.D. of the mean.
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Figure 2.

Retention factors measured for L-tryptophan at various flow rates for 5 μL injections of 20
μM L-tryptophan onto HSA microcolumns with lengths of (a) 2 cm, (b) 5 mm, or (c) 1 mm
and an inner diameter of 2.1 mm. Other experimental conditions are given in the text. The error
bars represent a range of ± 1 S.D. of the mean.
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Figure 3.
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(a) Typical chromatograms obtained for R-warfarin and L-tryptophan and (b) the resulting
selectivity factors determined R-warfarin versus L-tryptophan for HSA microcolumns. The
results in (a) were generated using HSA microcolumns with lengths of 20, 5 or 1 mm and an
inner diameter of 2.1 mm. Other experimental conditions are given in the text. The error bars
represent a range of ± 1 S.D. of the mean.
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Figure 4.

Plate height plots obtained for 5 μL injections of 20 μM R-warfarin onto HSA microcolumns
with lengths of (a) 2 cm, (b) 5 mm, or (c) 1 mm and an inner diameter of 2.1 mm. Other
experimental conditions are given in the text. The error bars represent a range of ± 1 S.D. of
the mean.
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Figure 5.
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Measured peak asymmetry at tenth height width for 5 μL injections of 20 μM R-warfarin onto
HSA microcolumns with lengths of (a) 2 cm or (b) 1 mm and an inner diameter of 2.1 mm.
Other experimental conditions are given in the text. The error bars represent a range of ± 1
S.D. of the mean.
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Figure 6.

Typical breakthrough curves obtained for racemic warfarin on HSA microcolumns. The results
in (a) and (b) were obtained at 0.5 mL/min on 2 cm and 1 mm long HSA microcolumns with
inner diameters of 2.1 mm and using warfarin concentrations (from left-to-right and top-tobottom) of 10, 5, 2.5, and 1 μM. The results in (c) were obtained for a 5 μM sample of warfarin
applied to a 1 mm × 2.1 mm i.d. HSA microcolumn at flow rates of 2.0, 1.0, 0.5, or 0.2 mL/
min. All of these experiments were conducted at pH 7.4 and 37 °C. Other experimental
conditions are given in the text.
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Figure 7.

Double-reciprocal frontal analysis plots prepared according to Eqn. (3) for the application of
warfarin at 0.5 mL/min to (a) a 2 cm or (b) a 1 mm long HSA microcolumn and an inner
diameter of 2.1 mm for samples with warfarin concentrations that ranged from 1 to 10 μM.
The equation for the best-fit lines were (a) y = 189 (± 3) x + 3.6 (± 0.2) × 107 (r = 0.9998) and
(b) y = 3895 (± 230) x + 8.8 (± 1.1) × 108 (r = 0.9965). The error bars represent a range of ± 1
S.D. of the mean.
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Table 1

Effect of column length and flow rate on frontal analysis results
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Column length (mm)

Flow rate (mL/min)

mL(nmol)

Ka(x 105 M−1)

20

0.5

27.5 (± 1.3)

1.9 (± 0.1)

1

27.8 (± 1.2)

1.9 (± 0.1)

2

27.6 (± 1.2)

2.0 (± 0.1)

Average b

27.6 (± 0.2)

2.0 (± 0.1)

0.5

10.0 (± 0.5)

2.8 (± 0.2)

1

9.5 (± 0.8)

3.1 (± 0.3)

2

9.7 (± 1.0)

3.0 (± 0.4)

Average b

9.7 (± 0.2)

3.0 (± 0.1)

0.5

3.9 (± 1.0)

3.7 (± 1.1)

1

4.3 (± 0.8)

3.0 (± 0.6)

2

4.2 (± 0.9)

3.5 (± 0.9)

Average b

4.1 (± 0.3)

3.4 (± 0.3)

0.2

3.6 (± 0.4)

2.5 (± 0.3)

0.5

3.7 (± 0.4)

2.4 (± 0.3)

1

3.8 (± 0.3)

2.3 (± 0.2)

2

4.2 (± 0.7)

2.2 (± 0.4)

Average b

3.8 (± 0.3)

2.3 (± 0.1)

0.2

2.3 (± 0.4)

2.3 (± 0.4)

0.5

2.5 (± 0.4)

2.1 (± 0.3)

1

2.5 (± 0.4)

2.2 (± 0.3)

2

2.9 (± 0.4)

1.9 (± 0.3)

Average b

2.6 (± 0.3)

2.1 (± 0.2)

0.2

1.2 (± 0.3)

2.3 (± 0.6)

0.5

1.3 (± 0.2)

2.1 (± 0.4)

1

1.2 (± 0.2)

2.2 (± 0.3)

2

1.0 (± 0.2)

3.7 (± 0.8)

Average b

1.2 (± 0.1)

2.6 (± 0.8)

10

5
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3

2

1

Relative Activity (vs. 20 mm column)a

1.0 (± 0.01)

0.68 (± 0.02)

0.58 (± 0.05)

0.92 (± 0.08)

0.92 (± 0.08)

0.83 (± 0.08)

NIH-PA Author Manuscript

a

These values were determined by comparing the specific activity measured for each column to the specific activity measured for the 2 cm long
column.
b

These values were determined by using the average for the various flow rates that were examined.
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